Why the study?
Does aspirin at different doses improve markers of inflammation, oxidative stress, insulin resistance, and endothelial function in patients with type 2 diabetes?
Population
17 subjects with type 2 diabetes, mean age 57.4 years, 12 male (71%)
Comparison
Aspirin 75 mg/day, 300 mg/day, or 3.6 g/day for… vs Placebo for 2 weeks
Design
RCT, random, sequential, blinded
Follow-up
2 weeks per intervention
Key result
Aspirin at 75 mg, 300 mg, or 3.6 g daily for 2 weeks had no significant impact on markers of vascular inflammation, oxidative stress, insulin resistance, or endothelial function in type 2 diabetes.
Authors
Loading...
Short-term aspirin lacks benefit on vascular or metabolic markers in type 2 diabetes; confirms neutral effects and challenges presumed pleiotropic actions.
RCT (n=17)
blinded
random, sequential
Does aspirin at different doses improve markers of inflammation, oxidative stress, insulin resistance, and endothelial function in patients with type 2 diabetes?
Short-term aspirin therapy at various doses does not significantly improve markers of vascular inflammation, oxidative stress, insulin resistance, or endothelial function in patients with type 2 diabetes.
Raghavan et al. (2013) conducted an RCT in type 2 diabetes (n=17). aspirin vs. placebo was evaluated on markers of vascular inflammation, oxidative stress, insulin resistance and endothelial function. Aspirin at 75 mg, 300 mg, or 3.6 g daily for 2 weeks had no significant impact on markers of vascular inflammation, oxidative stress, insulin resistance, or endothelial function in type 2 diabetes.